Gutiérrez-Amavizca BE, Figuera LE, Orozco-Castellanos R

Idioma: Español
Referencias bibliográficas: 32
Paginas: 157-161
Archivo PDF: 39.54 Kb.

RESUMEN

El síndrome de Kallmann se caracteriza por la combinación de hipogonadismo hipogonadotrópico y anosmia/hiposmia. El hipogonadismo hipogonadotrópico se debe a la deficiencia de la hormona liberadora de gonadotropinas ocasionada por un defecto en la migración de las neuronas sintetizadoras de la hormona liberadora de gonadotropinas, y la anosmia/hiposmia está relacionada con ausencia o hipoplasia del bulbo olfatorio y sus tractos. Algunos pacientes pueden presentar otras anormalidades como agenesia renal, paladar hendido, agenesia dental, sinquinesia refleja, acortamiento de metacarpianos, hipoacusia neurosensorial y convulsiones. Se presenta una revisión de las características clínicas y bases moleculares, donde se resalta la relevancia del conocimiento de variantes fenotípicas en síndrome de Kallmann.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kim H, Kurth I, Lan F, Meliciani I, Wenzel W, Eom S, et al. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2008;83(4):511- 519. Dispoible en http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2561938/?tool=pubmed

2. Ribeiro R, Vieira T, Abucham J. Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review. Eur J Endocrinol 2007;156(3):285-290.

3. Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidism. Am J Ment Defic 1944;48:203-236.

4. de Morsier G. Etudes sur les dysraphies cranioencephaliques. I. Agenesie des lobes olfactifs (telencephalo-schizis lateral) et des commissures calleuse et anterieure (telencephaloschizis median). La dysplasie olfacto genitale. Schweiz Arch Neurol Psychiat 1954;74(1):309-361.

5. Laitinen EM, Vaaralahti K, Tommiska J, Eklund E, Tervaniemi M, Valanne L, et al. Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland. Orphanet J Rare Dis 2011;6:41. Disponible en http://www. ncbi.nlm.nih.gov/pmc/articles/PMC3143089/?tool=pubmed

6. Fromantin M, Gineste J, Didier A, Rouvier J. Impuberism and hypogonadism at induction into military service. Statistical study. Probl Actuels Endocrinol Nutr 1973;16: 179-199.

7. Filippi G. Klinefelter’s syndrome in Sardinia. Clinical report of 265 hypogonadic males detected at the time of military check-up. Clin Genet 1986;30(4):276-284.

8. Seminara SB, Hayes FJ, Crowley WF. Gonadotropinreleasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev 1998;19(5):521-539. Disponible en http://edrv.endojournals. org/content/19/5/521.long

9. Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N, Kawakita S, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (Kal1) and fibroblast growth factor receptor 1 (FGFR1, Or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 2004;89(3): 1079-1088. Disponible en http://jcem.endojournals.org/ content/89/3/1079.long

10. Dodé C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler M, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor- 2. PLoS Genet. 2006:2(10):e175. Disponible en http://www. ncbi.nlm.nih.gov/pubmed/17054399

11. Trarbach E, Baptista M, Garmes H, Hackel C. Molecular analysis of KAL-1, GnRH-R, NELF and EBF2 genes in a series of Kallmann syndrome and normosmic hypogonadotropic hypogonadism patients. J Endocrinol 2005;187(3): 361-368. Disponible en http://joe.endocrinology-journals. org/content/187/3/361.long

12. Dodé C, Hardelin JP. Kallmann syndrome: fibroblast growth factor signaling insufficiency? J Mol Med 2004;82(11):725- 734.

13. Krams M, Quinton R, Ashburner J, Friston KJ, Frackowiak RS, Bouloux PM, et al. Kallmann’s syndrome: mirror movements associated with bilateral corticospinal tract hypertrophy. Neurology 1999;52(4):816-822.

14. Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, et al. A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal pathfinding molecules. Nature 1991;353(6344):529-536.

15. Legouis R, Cohen-Salmon M, del Castillo I, Levilliers J, Capy L, Mornow JP, et al. Characterization of the chicken and quail homologues of the human gene responsible for the X-linked Kallmann syndrome. Genomics 1993;17 (2):516-518.

16. Hardelin J, Dodé C. The Complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2. Sex Dev 2008;2(4-5):181-193.

17. Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, Soussi-Yanicostas N, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003;33(4):463-465.

18. Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, García- Piñero A, Wolczynski S,et al. A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab 2010;95(5):659-669.

19. Kim HG, Layman LC. The role of CHD7 and the newly identified WDR11 gene in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Mol Cell Endocrinol 2011;346(1-2):74-83.

20. Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008;118(8):2822-2831. Disponible en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2441855/?tool= pubmed

21. Kim HG, Bhagavath B, Layman LC. Clinical manifestations of impaired GnRH neuron development and function. Neurosignals 2008;16(2-3):165-182.

22. Soussi-Yanicostas N, Hardelin JP, Arroyo-Jiménez MM, Ardouin O, Legouis R, Levilliers J, et al. Initial characterization of anosmin-1, a putative extracellular matrix protein synthesized by definite neuronal cell populations in the central nervous system. J Cell Sci 1996;109 (Pt 7): 1749-1757.

23. González-Martínez D, Kim SH, Hu Y, Guimond S, Schofield J, Winyard P, et al. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfatedependent mechanism. J Neurosci 2004;24(46):10384- 10392.

24. Soussi-Yanicostas N, Faivre-Sarrailh C, Hardelin JP, Levilliers J, Rougon G, Petit C. Anosmin-1 underlying the X chromosome-linked Kallmann syndrome is an adhesion molecule that can modulate neurite growth in a cell-type specific manner. J Cell Sci 1998;111(Pt 19):2953-2965.

25. Hébert JM, Lin M, Partanen J, Rossant J, McConnell SK. FGF signaling through FGFR1 is required for olfactory bulb morphogenesis. Development 2003;130(6):1101-1111.

26. Carreras G, Udina M. Etiopathogenesis of Kallmann’s syndrome: genotype-phenotype associations. Endocrinol Nutr 2006;53(8):519-524.

27. Cariboni A, Maggi R. Kallmann’s syndrome, a neuronal migration defect. Cell Mol Life Sci 2006;63(21):2512-2526.

28. Quinton R, Duke VM, Robertson A, De Zoysa PA, Azcona C, MacColl GS, et al. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. Clin Endocrinol 2001;55(2):163-174.

29. Dode C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet 2009;17(2):139-146. Disponible en http://www.ncbi. nlm.nih.gov/pmc/articles/PMC2986064/?tool=pubmedb

30. KrzymiNska A, Hilczer M, HawuNa W, UlaNska A, Jakubowski L. Large deletion in the KAL1 gene in two related patients with hypogonadotropic hypogonadism: diagnostic usefulness of cytogenetic and molecular methods. Endokrynol Pol 2011;62(3):224-229.

31. Hou JW, Tsai WY, Wang TR. Detection of KAL1 gene deletion with fluorescence in situ hybridization. J Formos Med Assoc 1999;98(6):448-451.

32. Fu C, Feng Z, Liu RZ. Molecular genetics of Kallmann syndrome: an update. Zhonghua Nan Ke Xue 2011;17(4):361- 365.